Targeting paraoxonase-1 in atherosclerosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Paraoxonase-1 (PON1) is a Ca(2+) dependent, high-density lipoprotein-associated lactonase which is capable of retarding/inhibiting low-density lipoprotein (LDL) oxidation. LDL oxidation is believed to be central to the initiation and progression of atherosclerosis, therefore, PON1 is considered to be atheroprotective. AREAS COVERED: Relevant literature on PON1 was identified in PubMed. Here, we discuss the background to research on PON1 in atherosclerosis, the evidence for and against PON1 being atheroprotective, potential mechanisms of this atheroprotection and current knowledge on human PON1 regulation. EXPERT OPINION: Although current knowledge on PON1 indicates it to be atheroprotective, further clinical and basic studies are warranted to show that PON1 is causally linked to atherosclerosis, how it is atheroprotective and how it is regulated in vivo in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535 · cited 2×
“between healthy and CHD HDL was due to much lower PON1 activity associated with CHD HDL and hence a lower ability to remove the malondialdehyde [78].”
BackgroundDavidson, W. S., Silva, R. A. G. D., Chantepie, S., Lagor, W. R., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.186031 · Cited by 415
Cited by
Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis
Förstermann, U., Xia, N., & Li, H. (2017) · Circulation Research · doi:10.1161/circresaha.116.309326 · Cited by 1,519
Vascular oxidative stress, nitric oxide and atherosclerosis
Li, H., Horke, S., & Förstermann, U. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.001 · Cited by 656
Maslinic Acid, a Natural Phytoalexin-Type Triterpene from Olives — A Promising Nutraceutical?
Lozano-Mena, G., Sánchez-González, M., Juan, M., & Planas, J. (2014) · Molecules · doi:10.3390/molecules190811538 · Cited by 151
Bortolasci, C. C., Vargas, H. O., Souza-Nogueira, A., Barbosa, D. S., Moreira, E. G., Nunes, S. O. V., Berk, M., Dodd, S., & Maes, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.018 · Cited by 83
Effects of a 12-week aerobic exercise on markers of hypertension in men
Baghaiee, B., Karimi, P., Ebrahimi, K., Dabagh Nikoo kheslat, S., Sadeghi Zali, M. H., Daneshian Moghaddam, A. M., & Sadaghian, M. (2018) · Journal of Cardiovascular and Thoracic Research · doi:10.15171/jcvtr.2018.26 · Cited by 14
Metadata
- Authors
- Mackness, M., & Mackness, B.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2013-04-10
- Volume
- 17
- Issue
- 7
- Pages
- 829-837
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2084040238
- Cited by
- 58
- References
- 4
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting paraoxonase-1 in atherosclerosis. https://app.cochat.ai/papers/10.1517/14728222.2013.790367
- The paper
- Mackness, M., & Mackness, B. (2013). Targeting paraoxonase-1 in atherosclerosis. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2013.790367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.